

Disorders of Diminished Motivation: Diagnosis, Assessment Treatment, and Emerging Treatment Options: A Rehabilitation Perspective

Abstract

Disorders of diminished motivation broadly categorized range from Apathy syndrome on the mild end of the spectrum to Abulia, with the most severe form being Akinetic Mutism. These disorders significantly affect all domains of an individual's physical, functional, and psychosocial aspects of life. The decreased meaningful engagement of such an individual lead to an inferior quality of life and a care burden. This narrative review of this spectrum of illness attempts to provide an overall understanding of pathophysiology, available diagnostic tools, treatment interventions, current gaps, and relevant rehabilitation needs to provide better outcomes. It is acknowledged that this cannot be an all-encompassing discussion of these disorders and that further research is required to enable better delineation of such disorders and the overall impact on health outcomes across various populations.

Introduction

Disorders of diminished motivation (DDM) are a significant scientific endeavour. They are the most pervasive and disabling class of brain injury symptoms following traumatic brain injury (TBI), which lead to worse rehabilitation outcomes, reduced quality of life, and participation in community life [1]. This review discusses the aetiology and pathophysiology of this spectrum of disorders, which encompasses a continuum from apathy syndrome through abulia to akinetic mutism. It provides an overview of the definition, diagnosis, assessment, treatment, and future direction of treatment options [2].

Definition and Types of Disorders of Diminished Motivation

Motivation is defined as the "traits and underlying mechanisms of goal-directed behaviour, along with the

Review Article

Bala Vaidya^{1*} and Baytieh Lina²

¹Doctor of Health Science trainee, Campbell University, Raleigh, NC, USA Medical Co-Director, Department of Population and Public Health, Illawarra and Shoalhaven Local Health District, The Wollongong Hospital, Wollongong, NSW, Australia.

***Correspondence:** Bala Vaidya, Department of Population and Public Health, ISLHD Hospitals Wollongong NSW AU, Email: Vaidya.Balasubramaniam@health.nsw.gov.au

Received: 27 September, 2024; **Accepted:** 29 October, 2024; **Published:** 05 November, 2024.

Copyright: © 2024 Vaidya B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

processes by which behaviour is begun, energized, sustained, directed, and stopped" [3].

Types of DDM

Apathy Syndrome: A primary motivational loss that is not attributable to emotional distress, intellectual impairment, or diminished consciousness. Patients are regular in cognition, emotion, attention, and behaviour, but to a lesser extent.

Abulia: Poor behaviour and speech, poor initiation, loss of emotional reaction, psychomotor slowing. A more benign form of akinetic mutism.

Akinetic Mutism: Silence and lack of movement when there are intact pathways from the sensorimotor cortex to voluntary motor areas. It can be caused by damage to bilateral frontal lobes.

Diagnosis of DDM

Criteria for Apathy Syndrome

Diminished Goal-Directed Behaviour: Lack of productivity, effort, and time spent in activities of interest. Dependence on others for structuring activities. Diminished socialization and recreation.

Diminished Goal-Directed Cognition: Lack of interest in learning new things and health concerns. Diminished value attributed to goal-directed behaviour.

Diminished Emotional Concomitants: Unchanging affect and lack of emotional response to events.

Aetiology

Frontal lobe lesions, acquired brain injury, stroke, dementia, and other neurological conditions [4].

Assessment of DDM

Apathy Evaluation Scale (AES)

- The AES developed by Robert S. Marin includes cognitive, behavioural, and emotional aspects.
- Versions: Clinician, Subjective, Informant.
- Scale: The higher the score, the greater the severity of apathy; the classifications run from average to profound apathy [5].

Neuroanatomical and Neurochemical Mechanisms

- Core circuits: Nucleus accumbens, ventral pallidum, ventral tegmental area.
- The limbic system and prefrontal cortex connections.
- Dopamine, glutamate, and cholinergic systems influence motivation and reward [6].

Treatment Options for DDM

Multidisciplinary Approach

- Early management and identification of any secondary medical illness, such as anaemia, chronic disease, hypothyroidism, etc.

Environmental Interventions:

- Improve lighting, normalize diurnal patterns, minimize white noise, and increase social outlets.

Psychological and Behavioural Interventions

- Develop individualized plans with short-term goals and provide positive reinforcement.

Pharmacological Treatments:

- Dopamine agonists (bromocriptine, amantadine, levodopa).
- Antidepressants (venlafaxine, tranylcypromine, mirtazapine).

Emerging Treatment and Future Directions for Further Research

Pharmacological Treatments

Dopaminergic agents: Psychostimulants like amphetamine, methylphenidate, and modafinil are being studied as potential ways to improve motivation.

Dopamine receptor agonists: Pramipexole, ropinirole, and rotigotine activate dopamine receptors directly.

Dopamine reuptake inhibitors: Bupropion and some other medications block the reabsorption of dopamine into nerve cells, thus increasing dopamine's availability in brain regions associated with reward.

Monoamine oxidase inhibitors (MAOIs): Selegiline and Rasagiline prevent the breakdown of dopamine and might further enhance motivational states.

Catecholaminergic activity enhancers (CAEs): Selegiline

may boost dopamine through the MAOI and CAE effects.

Non-Pharmacological Treatments

Neuromodulation techniques: Transcranial Magnetic Stimulation (TMS) and Deep Brain Stimulation (DBS) are being evaluated for their ability to modulate brain activity in regions such as the prefrontal cortex.

Behavioural and cognitive interventions: Behavioural Activation therapy and Cognitive Behavioural Therapy (CBT) aid patients in identifying negative thought processes and fostering changes that restore motivation.

Mindfulness and physical exercise: Mindfulness meditation practices and physical exercise can improve attention, reduce stress, and enhance general mental health, leading to improved motivation.

Future Directions

Gene therapy: The responsible use of gene therapy may one day target errors in the biology of motivation and reward.

Neuro feedback: Neurofeedback training teaches self-regulation through live monitoring of brain activity and associated responses.

Personalized medicine: These pioneering research tools herald a new age of treatment plans tailored to our neurobiological profile.

Potential Challenges with Assessment, Diagnosis, and Treatment of DDM

The complex nature of DDMs and their fuzzy boundaries make treating them challenging. Here are some of the many obstacles:

Diagnostic Complexity

Diagnostic overlap with other conditions: DDM often overlaps with other psychiatric and neurological conditions such as depression, schizophrenia, and dementia, consequently making it challenging to diagnose correctly.

Lack of standardised diagnostic criterion: The absence

of an agreed-upon diagnostic criterion creates a problem regarding consistency in diagnosing and treating DDM.

Assessment Difficulties

Motivation: Motivation is inferential, dependent on self-reported measures, and often prone to inaccuracy.

Tools to assess apathy disregard other motivational symptoms. Although useful as a general assessment, the Apathy Evaluation Scale (AES) takes a long time to administer and must be administered and scored by a trained professional.

Treatment Limitations

Pharmacological tolerance and side effects: Dopamine agonists and antidepressants have side effects that gradually diminish their efficacy over time. They also can have profoundly serious side effects.

Low efficacy: Not all patients respond to pharmacological treatments, and the efficacy can vary widely from person to person.

Non-pharmacological interventions: Environmental and Behavioural Interventions require intensive resources and sustained delivery in under-resourced settings, which can be extremely difficult.

Multidisciplinary, coordinated efforts across medical and mental health professionals can be essential for an effective and integrated recovery process, but these services can be difficult to consolidate.

Patient and Caregiver Factors

Patient compliance: Patients with DDM might not care as much about going to therapy sessions or taking medicines on a regular schedule.

Caregiver burden: Burnout and the other effects of long-term care on caregivers affect the treatment relationship.

Research and Knowledge Gaps

Reduced research: The mechanisms by which DDM works are still poorly understood, and we cannot treat

what we cannot diagnose. It is a very variable illness, with symptoms and severity highly variable, making it challenging to develop treatment protocols. DDM can cause extreme agitation and distress and poor outcomes, including suicide.

Addressing the Challenges

To address these challenges, a comprehensive and individualized approach is essential. This includes:

Improving diagnostic tools: Developing more objective and standardized diagnostic criteria.

Increasing effective measurement: New imaging techniques and biomarkers are used to explore DDM and assess it more effectively.

Optimizing treatment plans: Combining pharmacological and non-pharmacological interventions tailored to individual patient needs.

References

1. Marin, Robert S, and Patricia A. Wilkosz. "Disorders of diminished motivation." *The Journal of head trauma rehabilitation* 20 (2005): 377-388.
2. Spiegel, David R, Alyssa Warren, Will Takakura and Lia Servidio, et al. "Disorders of diminished motivation: what they are, and how to treat them." *Curr Psychiatry* 17 (2018): 10-18.
3. Simpson, Eleanor H, and Peter D. Balsam. *The behavioral neuroscience of motivation: an overview of concepts, measures, and translational applications.* Springer International Publishing, (2016).
4. Starkstein, Sergio E, and Jaime Pahissa. "Disorders of Diminished Motivation." *Textbook of Traumatic Brain Injury* (2018): 381.
5. Duffy, James D. "The neural substrates of motivation." *Psychiatric Annals* 27 (1997): 24-29.
6. Salamone, John D, Samantha E. Yohn, Laura López-Cruz and Noemí San Miguel, et al. "Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology." *Brain* 139 (2016): 1325-1347.

Supporting caregivers: Provide resources and support for caregivers so they can do less, and their patients can do better.

Encouraging research: Conduct more research on performing DDM to complete our understanding of its mechanisms and treatment.

Conclusion

There is an increasing recognition of the importance of assessing and treating DDM in designing rehabilitation for patients with TBI to improve their quality of life. DDM's multifactorial intervention encompasses medical, environmental, psychological, and pharmacological approaches. These constitute the core of the present review, which is intended to introduce the reader to the current knowledge of important aspects of DDM, its conceptual framework with particular emphasis on the role of motivation in successful rehabilitation, and strategies of diagnosis, assessment, and treatment.

Citation: Bala Vaidya. "Disorders of Diminished Motivation: Diagnosis, Assessment Treatment, and Emerging Treatment Options: A Rehabilitation Perspective." *J Neur Imag Neur Med* (2024): 108. DOI: [10.59462/JNINM.2.1.108](https://doi.org/10.59462/JNINM.2.1.108)